Bragar Eagel & Squire investigates Sionna Therapeutics after 91% stock plunge

Sep 2, 2026 18:54 (20d ago)

Verifying

Bragar Eagel & Squire is investigating potential claims against Sionna Therapeutics for stockholders.
Sionna Therapeutics stock fell more than 91% after the company disclosed the trial result.
Sionna Therapeutics announced the SION-719 trial outcome on Aug. 10, 2026.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.